IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 24.8

Change

-0.08 (-0.32)%

Market Cap

USD 0.14B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-31 )

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.78% 43% F 60% D-
Dividend Return 0.48% 53% F 10% F
Total Return 8.26% 48% F 54% F
Trailing 12 Months  
Capital Gain 9.98% 43% F 60% D-
Dividend Return 1.24% 72% C 17% F
Total Return 11.22% 43% F 54% F
Trailing 5 Years  
Capital Gain -8.06% 5% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.06% 5% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain -0.26% 14% F 39% F
Dividend Return 0.19% 14% F 30% F
Total Return 0.45% 53% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 37.24% 5% F 26% F
Risk Adjusted Return 0.51% 14% F 28% F
Market Capitalization 0.14B 60% D- 31% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.